Urate-Lowering Therapy in Cardiovascular Pharmacotherapy: From Mendelian Randomization Data to Cardio–Renal–Metabolic Risk Modulation
Authors
Discussion
Loading...
Member takes
Overview
Review integrates epidemiological, Mendelian randomization, and pharmacological evidence on urate-lowering therapy in cardiovascular risk modulation.
Key Points
- This review aims to define the role of serum uric acid and urate-lowering therapy in cardiovascular care.
- Synthesized population-based studies, Mendelian randomization analyses, and randomized trials of various urate-modifying agents.
- Examined the relationships between higher serum uric acid levels and cardiovascular conditions in diverse populations.
- Analyzed the effectiveness and safety profiles of xanthine oxidase inhibitors, uricosurics, and biologic uricases.
- No consistent reduction in cardiovascular events with urate-lowering therapy in asymptomatic hyperuricemia and stable ischemic heart disease.
- Observational data suggest long-term use of xanthine oxidase inhibitors may reduce coronary risk under certain conditions.
- Mendelian randomization indicates a modest causal effect of elevated serum uric acid on blood pressure and coronary disease.
Cite This Study
Borghi et al. (2026) studied this question.